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Bioinformatics toolSomatically acquired chromosomal rearrangements occur at early stages during tumorigenesis and can be used
to indirectly detect tumor cells, serving as highly sensitive and tumor-speciﬁc biomarkers. Advances in high-
throughput sequencing have allowed the genome-wide identiﬁcation of patient-speciﬁc chromosomal
rearrangements to be used as personalized biomarkers to efﬁciently assess response to treatment, detect residual
disease andmonitor disease recurrence. However, sequencing and data processing costs still representmajor ob-
stacles for the widespread application of personalized biomarkers in oncology. We developed a computational
pipeline (ICRmax) for the cost-effective identiﬁcation of a minimal set of tumor-speciﬁc interchromosomal
rearrangements (ICRs). We examined ICRmax performance on sequencing data from rectal tumors and simulat-
ed data achieving an average accuracy of 68% for ICR identiﬁcation. ICRmax identiﬁes ICRs from low-coverage
sequenced tumors, eliminates the need to sequence a matched normal tissue and signiﬁcantly reduces the
costs that limit the utilization of personalized biomarkers in the clinical setting.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Somatically acquired chromosomal rearrangements, including du-
plications, inversions, deletions, insertions and translocations, consti-
tute a key feature of tumor genomes [1–3]. They occur at early stages
during tumor formation and persist throughout tumor progression [4].
These rearrangements are not present in normal cells from cancer pa-
tients and can thus be used to unequivocally detect tumor cells, serving
as highly sensitive and speciﬁc tumor biomarkers to approach clinically
relevant endpoints, such as assessment of response to therapy and
detection of disease recurrence [5–7].
Technically, PCR detection of translocated DNA sequences that
originate from different chromosomes or thousands of base pairs apart
is a straightforward process when compared to PCR discrimination of
single-base alterations and, therefore, tumor-speciﬁc chromosomal re-
arrangements represent ideal markers for monitoring tumor burden
[5,8]. Highly sensitive and speciﬁc assays developed to detect recurrent
chromosomal translocations in hematological tumors have become
standard practice to monitor residual disease and predict relapse to
targeted therapy, allowing individualized therapeutic choices [9,10].e).
. This is an open access article underUnfortunately, a similar use of known chromosomal rearrangements
in solid tumors has been hampered by the absence of recurrent rear-
rangements in these tumors [3]. Recently, however, whole-genome
sequencing has become efﬁcient and affordable enough to allow
genome-wide identiﬁcation of patient-speciﬁc somatic chromosomal
rearrangements [2,11–13] that could be used as personalized bio-
markers to detect tumor cells [5].
Currently, analysis of short read paired-end or mate-pair sequences
aligned against the human reference genome is the most efﬁcient strat-
egy to detect somatic chromosomal rearrangements present in tumor
genomes. However, due to the repetitive nature of the human genome
and the presence of structural variations, assigning the correct mapping
positions to short reads and calling somatic chromosomal rearrange-
ments are not straightforward processes [1,14], and a large number of
false positive candidates are usually identiﬁed [3], generating unaccept-
able levels of noise. In order to reduce the high number of false positives
candidates and analysis complexity, sequencing of a matched normal
tissue DNA sample is usually required [15,16], increasing both the
sequencing and computational costs, and further limiting the use of
this strategy in actual clinical practice. Some of the most used software
currently available for structural variation (SV) detection show good
precision and high sensitivity for detecting inter-chromosomal rear-
rangements, such as BreakDancer [15], CREST [17], HYDRA-SV [18]the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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quencing, or dispense with thematched normal sequencing but require
high sequence coverage to identify correct breakpoints through split
mapped read analysis, hampering the clinical application of these tools.
Here we present a pipeline (ICRmax) that allows the efﬁcient iden-
tiﬁcation of tumor-speciﬁc interchromosomal rearrangements. ICRmax
has sets of ﬁlters that efﬁciently eliminate the need to sequence a
matched normal genome and to allow the efﬁcient identiﬁcation of in-
terchromosomal rearrangements from low-coverage (~3×) sequenced
tumor genomes. The use of ICRmax signiﬁcantly reduces the sequencing
and computational costs associated with the identiﬁcation of tumor-
speciﬁc chromosomal rearrangements and will certainly contribute to
the widespread use of personalized biomarkers in the routine clinical
practice of patients with solid tumors.
2. Results and discussion
2.1. ICRmax implementation and ﬁlters
ICRmax was developed to efﬁciently identify a minimal set of reli-
able interchromosomal rearrangements from low coverage sequenced
tumor genomes without the need to sequence a matched normal
genome, reducing the sequencing cost and creating an opportunity to
implement the use of personalized biomarkers in the routine clinical
management of solid tumors. The ICRmax pipeline, described withFig. 1. Bioinformatics pipeline showing the main steps for whole tumor genome analysis and s
somal rearrangements.details inMethods, is summarized in Fig. 1 and a step-by-step command
line are provided in the supplementary material.
2.2. Identiﬁcation of interchromosomal rearrangements in rectal tumors
with ICRmax
In order to show how our pipeline works, we used ICRmax to
identify interchromosomal rearrangements in six rectal tumor genomes
(RT1–RT6). For each sample,mate-pair libraries with average insert size
of 600 bpwere generated using tumor genomic DNAand sequenced in a
SOLiD sequencing platform to varying depths (see Table 1). Sequenced
reads were aligned against the human genome reference sequence
using Bioscope (Applied Biosystems) and only high quality (Q N20)
alignmentswere selected for further analysis. Sequence coverage varied
from 4 to 9× and the calculated physical coverage based on the average
insert size of sequenced fragments varied between 15 to 62×. The insert
size of ~600 bp for the libraries yields a higher physical coverage with
lower sequencing depth and facilitates the identiﬁcation of structural
variation [1] also contributing to lowering the cost associated to this
protocol since smaller insert size libraries (~200 bp) will probably re-
quire higher sequencing depth. Sequencing and coverage information
for each tumor sample is presented in Table 1. We also sequenced
threematched normal genomes (N1, N5 and N6) and submitted the se-
quenced reads through the same pipeline to evaluate their contribution
to exclude false positive events that were not ﬁltered out by ICRmax.election of sequences indicating the presence of structural variation such as interchromo-
Table 1
Mapping results for rectal tumor samples and paired normal tissue samples submitted
through whole genome sequencing.
Sample Total reads Mapped nucleotides Physical coverage Sequence
coverage
RT1 1,035,604,016 25,967,977,794 (50%) 180,593,981,498 (62×) 9.0×
RT2 393,756,912 12,232,074,899 (62%) 57,714,657,702 (20×) 4.2×
RT3 385,789,584 11,616,923,871 (60%) 53,821,366,172 (19×) 4.0×
RT4 398,436,826 12,231,994,959 (61%) 59,355,360,167 (20×) 4.2×
RT5 425,460,416 15,150,461,585 (51%) 42,211,056,664 (15×) 5.2×
RT6 991,625,036 20,921,867,961 (42%) 77,491,127,440 (27×) 7.2×
N1 728,574,754 21,532,212,957 (49%) 78,716,757,426 (27×) 7.4×
N5 682,517,714 26,824,738,972 (65%) 94,020,024,357 (32×) 9.3×
N6 305,101,394 9,129,663,072 (60%) 43,929,159,747 (15×) 3.2×
Table 2
Validation results.
Sample Number of
clusters
Rearrangements after
recurrent ﬁlter
Tested
rearrangements
Validated as
tumor speciﬁc
RT1 27 10 6 3 (50.0%)
RT2 18 15 10 9 (90.0%)
RT3 9 4 4 3 (75.0%)
RT4 105 96 11 1 (9.0%)
RT5 14 2 1 1 (100.0%)
RT6 19 14 4 1 (25.0%)
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varied from 3.2 to 9.3× and from 15 to 32×, respectively (Table 1).
ICRmax pipeline was followed as described in the Methods section
and supplementary material. Some of the ﬁltering steps involve regions
that cause misalignment and are also included in other pipelines for
detecting structural variations [15,18]. However, they are usually not
as comprehensive or strict since there are repetitive genomic regions
that can yield uniquely mapped reads. In our experience, detection of
somatic structural variation beneﬁts from this strict ﬁltering approach.
As expected, a variable number of putative interchromosomal rear-
rangements were identiﬁed in each tumor genome (ranging from 9 to
105 events per sample, average of 32). Interestingly, when we com-
pared the set of ICR candidates in each tumor genomewe found a signif-
icant number of recurrent events (Table S1). Since solid tumors are well
known for their lack of recurrent tumor-speciﬁc rearrangements [3] we
assumed that these recurrent events (Table S1) might correspond to
artifacts that could be removed by comparison with the matched nor-
mal samples [19–21]. The presence of recurrent structural variation
breakpoints was recently observed in a study of complex genomic rear-
rangements [22] and as a validation strategy only breakpoints present
in a single tumor were considered somatic. Accordingly, we selected
eight tumor-recurrent events for validation by PCR ampliﬁcation with
primers ﬂanking the putative breakpoint region determined by the
alignment ofmate pair reads. As expected for such false positive somatic
events, ampliﬁcation with speciﬁc primers was obtained when using
both the tumor and matched normal DNA (Figure S2) and these cases
are therefore not candidates for tumor-speciﬁc rearrangements. We
therefore implemented this inter-tumor comparison as a last ﬁltering
step in our ICRmax pipeline, removing all the identiﬁed recurrent
artifacts in our tumor genomes from the ﬁnal set of rearrangement
candidates. The ﬁnal sets of rearrangements found are represented in
Fig. 2 and Fig. S3 using Circos [23].Fig. 2. Circos representation of the interchromosomal rearrangements found in 3 tumor genomWe generated a list of recurrent artifacts that is available as supple-
mentary data (Table S2), or directly at http://www.bioinfo.mochsl.org.
br/icrmax (ﬁle recurrent_artifacts.bed).
Thus, ICRmax does not rely on the need to sequence matched
normal/tumor genomes due to the implementation of additional ﬁlters
to remove recurrent events and to eliminate false-positive rearrange-
ments, reducing by at least half the sequencing cost, but still allowing
the identiﬁcation of a reliable minimal set of tumor speciﬁc ICRs for
clinical application. To the best of our knowledge, this is the ﬁrst
pipeline for detection of somatic structural variations that dispenses
with the sequencing of matched normal genome.
After removing recurrent artifacts and false-positive candidates, the
number of identiﬁed events for each sample varied from2 to 96,with an
average of 23 per sample (detailed in Table 2). Rearrangements present
in each sample are graphically represented in Fig. 2 and Supplementary
Fig. 3. A subset of theses putative rearrangements was then selected for
PCR validation followed by Sanger sequencing (Table 2). Of the 36 puta-
tive interchromosomal rearrangements selected for validation, 18 (50%)
were conﬁrmed as somatic tumor-speciﬁc events and their exact
breakpoints were determined for most cases after sequencing (PCR
ampliﬁcation results are shown in Supplementary Fig. 2). Validation ef-
ﬁciency between different samples varied from 9 to 90%, and some pa-
tients, like RT4, providedmore difﬁculty in the validation stage, possibly
due to the presence of different levels of genetic instability and tumor
heterogeneity. Fig. 3 illustrates the genomic region, as well as the se-
quence coverage, of a conﬁrmed rearrangement between chromosomes
1 and 17 detected in sample RT2. The exact breakpoint was determined
by PCR ampliﬁcation followed by Sanger sequencing of the ampliﬁed
fragment (see Supplementary Fig. 4). Interestingly, this rearrangement
is located in the TP53BP2 gene region, and loss of this functional gene
product has been associatedwith gastric and other cancer susceptibility
[24].
These validated rearrangements can be used in further investigation
as biomarkers for their corresponding patients. The validation stage
is essential in distinguishing tumor speciﬁc events from germline
polymorphisms or false positives candidates. Furthermore, one couldes. a) RT1; 10 rearrangements b) RT2; 15 rearrangements and c) RT3; 4 rearrangements.
Fig. 3.Genome browser viewof reads (green) indicating one of RT2 rearrangements between chromosome 17 (left) and chromosome 1 (right). Region shown for chromosome 17 ends in
the breakpoint found after Sanger sequencing. Region shown for chromosome 1 also starts in the exact breakpoint nucleotide. Read orientation indicates that the rearrangement is
structured as shown and conﬁrmed through Sanger sequencing. The nucleotide sequence of the breakpoint region is shown above. Last nucleotide of chromosome 17 and ﬁrst nucleotide
of chromosome 1 are marked in red. Sequence coverage is shown in dark blue, and only reads with mapping quality ≥20 are used.
Table 3
Mapping results for genomes containing randomly simulated ICRs.
Simulated
genomes
Reads
generated
Mapped reads Sequence
coverage
Physical
coverage
RG1 402,771,620 336,548,722 (83.5%) 5.8× 44×
RG2 263,391,883 221,636,923 (84.1%) 3.8× 25×
RG3 131,695,960 110,878,325 (84.2%) 1.9× 13×
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speciﬁc events. However, the costs of primer design and the time
spent on breakpoint ampliﬁcation can be a limiting factor when identi-
fying personalized chromosomal rearrangements in the clinical setting.
The optimization of the bioinformatics analysis is therefore critical
for deﬁning a concise set of reliable rearrangements to substantially
increase the efﬁciency of the entire process.
2.3. Comparison to a tumor-normal paired sequencing
As previously mentioned, to assess the contribution of sequencing
matched normal genomes when using ICRmax, we sequenced matched
normal DNA for three of our tumor samples. Sequencing and coverage
information for all normal samples is presented in Table 1. We found
that most (62%) of the ICR candidates detected in both normal and
tumor DNA were also detected in other tumor samples and therefore
present in our list of recurrent artifacts. For instance, 13 events were
detected in both N1 and RT1 samples derived from the same patient,
but 10 of these rearrangements were also present in our list of tumor-
recurrent artifacts. Interestingly the number of events ﬁltered by the
recurrent artifact listwas for some of the samples greater than the num-
ber of events removed exclusively by comparison to the matched nor-
mal genomes. For example, for patient #1 a total of 3 rearrangements
that were not identiﬁed by sequencing the matched normal genome
were ﬁltered out using the list of tumor-recurrent rearrangements and
one extra event was removed by comparison with one of the other nor-
mal tissues sequenced. Similar results were observed for the other two
patients for whom we have sequenced the matched normal DNA
(Table S1). Noteworthy, for patient #6, sequencing thematched normal
DNA (N6) removed only four rearrangements found in the tumor
genome (and only one of these could not be removed by the tumor-
recurrent list), likely due to the low coverage obtained for the normal
sample (Table 1), suggesting that sequencing paired normal tissue
with lower coverage is not an effective option to remove false-positive
candidates. The matched normal tissue contribution therefore does
not justify the increase in the sequencing cost, since a search for recur-
rent events in different tumor genomes allows the efﬁcient identiﬁca-
tion of artifactual events.
2.4. Expansion of the recurrent artifacts list
One of the main conclusions from our analysis of structural varia-
tions in rectal tumor genomes was that removing recurrent events re-
duces substantially the cost and time of analysis for the validations in
the personalized approach, dispensing with the sequencing of matched
normal DNA. Currently, a large amount of data is available from large-
scale genome sequencing projects (normal and tumor). We sought to
expand our recurrent artifact list and improve our capability to exclude
these events from future analysis by applying our pipeline to the 2362
individuals from the 1000 Genomes project [25]. The results from our
analysis reveal a total of 2800 events indicating interchromosomal
rearrangements that are recurrent in three or more individuals. From
the 31 cases of recurrent artifacts identiﬁed in our six rectal tumor
genomes, 16 are present in this set found for individuals of the 1000Genomes project. There are also three events in the 1000 Genome re-
current set that are present in our ﬁnal candidate set for the patients
(not eliminated by any ﬁlter). Two of these events had in fact been test-
ed by PCR to validate them as tumor-speciﬁc and resulted in normal
DNA ampliﬁcation. Therefore, this analysis of 2362 normal genomes
substantially increases our list of recurrent artifacts to exclude from
future analysis of tumor-speciﬁc structural variations. The list of 2800
recurrent interchromosomal events can also be downloaded from
http://www.bioinfo.mochsl.org.br/icrmax. We expect that even more
recurrent artifacts can be identiﬁed and excluded through the analysis
of data available from tumor genomes already sequenced andwe intend
to continue to increase this list.
2.5. Simulated rearrangement datasets
Overall, our pipeline was effective when applied to the tumor ge-
nomes sequenced and allowed the identiﬁcation of a minimal subset
of personalized interchromosomal rearrangements. However, tumor
heterogeneity and genetic instability prevents both the complete iden-
tiﬁcation of rearrangements present in the tumor genome as well as a
true estimate of our method's accuracy. In order to better evaluate our
pipeline we simulated three human genomes (based on hg19) contain-
ing different numbers of ICRs. We randomly created 20, 30 and 40 ICR
events for each genome (RG1, RG2 and RG3, respectively; for details,
see Methods and Supplementary data). From each genome (RG1, RG2
and RG3) we also generated three sets of randomly sampled reads
(mate pairs of 50 nt and insert size of 700 nt, on average), which repre-
sent a simulated physical coverage of 44×, 25× and 13×, respectively
(see Table 3). Using ICRmax and increasing the minimal mate pair sup-
port to ﬁve reads, we were able to correctly identify 42 out of the 90
simulated rearrangements (47% speciﬁcity) and eight additional false
positive candidates (84% accuracy; Table 4). As expected, for the low se-
quence coverage genomes (1.9× and 3.8×; Table 3), ICRmax performed
with a lower sensitivity (42.5%), but a remarkable accuracy (100%).
When we decrease the mate pair support requirement to three reads
in the RG2 and RG3 simulated genomes, we detected a higher number
of true simulated rearrangements (18/30 for RG2 and 20/40 for RG3)
but a number of false positives also appear in the sets (14 for RG2 and
3 for RG3). The results presented in Table 4 suggest that our pipeline
achieved an experimentally acceptable accuracy and sensitivity for ICR
detection and performed well even under low sequencing (1.9×) and
physical (13×) coverage (for RG3, for instance). Further details on
the simulated reads can be found in the Methods section and results
regarding our simulated data are presented in Tables 3 and 4 and
Supplementary Fig. 3.
Table 4
Identiﬁcation of simulated events by ICRmax.
Simulated
genomes
Simulated
ICRs
Found ICRs
(ﬁnal set)
True positives
(accuracy)
Sensitivity
RG1 20 21 13 (62%) 65% (13/20)
RG2 30 15 15 (100%) 50% (15/30)
RG3 40 14 14 (100%) 35% (14/40)
Total 90 50 42 (84%) 47% (42/90)
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gorithm [18]. HYDRA successfully detected 58 out of the 90 simulated
rearrangements, yielding higher sensitivity (64%) but poorer accuracy
in all three sets (Table S4). There is an increase in the number of
breakpoints detected that do not correspond to the simulated rear-
rangements, including in RG2 and RG3, for which the ICRmax pipeline
only detected the true simulated breakpoints. Similar to ICRmax,
HYDRA performed with higher accuracy in the simulated datasets that
had lower coverage.
2.6. Pipeline test in a different tumor type and different sample source
To better establish the robustness of our pipeline and its perfor-
mancewith data generated using different sequencing platforms, tissue
sources and tumor type, we used data from a study on breast cancer
genome evolution [26]. For four of the patients in the original study
(P1, P4, P5 and P6), we downloaded whole genome sequencing data
from FFPE samples corresponding to invasive ductal carcinoma (IDC)
or matched normal tissue from lymph nodes (Lymph). After alignment
and duplicate read removal, the number of reads per sample was on av-
erage ~7million, and the insert size for these libraries was ~300–400 bp
according to the original study. We submitted these reads through the
ICRmax pipeline, and detected interchromosomal rearrangements for
each patient (4, 6, 7, and 5 respectively). We then performed either
our ﬁnal step in the pipeline, the inter-tumor comparison, or the usual
matched normal comparison. Overall, we detected 4 recurrent artifacts
in two or more of the patients. After removal of these artifacts, the ﬁnal
sets contained 2, 2, 5 and 2 rearrangements respectively. If instead we
perform a usual tumor vs. normal comparison in the initial set, we iden-
tify 2 artifacts and remove them from each paired sample. The resulting
sets contain 3, 3, 5 and 2 rearrangements. Consequently, with the inter-
tumor comparison we were able to detect and remove two additional
artifacts. The artifacts detected are not the same. Of the 4 artifacts iden-
tiﬁed by the inter-tumor comparison, only, one was identiﬁed by the
matched normal comparison. Therefore there is a single artifact identi-
ﬁed bymatched normal comparison that cannot be removed otherwise,
and three artifacts removed by the inter-tumor comparison that are not
detected in the matched normal.
If we compare the ﬁnal set of results from the IDC samples to the
recurrent artifact list we generated from 1000 Genomes, we ﬁnd an
additional 2 artifacts that can be removed from the set thus reinforcing
the value of building a database with recurrent artifacts found in both
tumor and normal samples.
2.7. Cost analysis
Based on the data presented here, we estimated the ﬁnal cost asso-
ciatedwith the immediate application of this protocol in the clinical set-
ting. At our facilities, the sequencing cost in the SOLiD 5500XL platform
is approximately US$1 per 20 million bases. To obtain a 4× sequencing
coverage for each patient sample, one needs to generate ~20 billion
bases (400 million reads with 50 nt), totalizing ~US$1000 per patient.
For each patient the ﬁnal cost for the development of personalized chro-
mosomal rearrangements should include additional costs for sample
processing and mate-pair library construction (~US$470 per patient)
as well as for PCR validation. Testing 10 putative rearrangements willcost ~US$200 in primer synthesis and ~US$10 for all PCR reactions. As-
suming a 50% validation rate, subsequent Sanger sequencing of the ﬁve
PCR-validated rearrangements for breakpoint determinationwould add
~US$50 reaching the ﬁnal cost of ~US$1730 per patient.
3. Conclusion
Recent advances in high throughput sequencing technology have
allowed the genome-wide identiﬁcation of patient-speciﬁc chromo-
somal rearrangements [2,3,5,6,16]. These personalized biomarkers are
especially useful to assess response to treatment, detect residual disease
and monitor disease recurrence and are expected to have a widespread
use in clinical oncology [5,6]. Unfortunately, current methods for chro-
mosomal rearrangement detection require the sequencing of both
tumor and matched normal genomes increasing the sequencing and
computational costs and precluding the implementation of personal-
ized biomarkers in clinical practice [15,16]. ICRmax aims to eliminate
this need, relying on a set of strict mapping ﬁlters and inter-tumoral
comparison to greatly reduce false positive candidates. However it is
important to emphasize that the main goal is not to obtain the full set
of ICR events present in the tumor genome, but to efﬁciently identify a
minimal set of rearrangements which in any case can only represent
part of a much larger set of tumor alterations due to the percentage of
a solid tumor collected in a biopsy, for example. The minimal set of
identiﬁed rearrangements can be validated and included into practice,
reducing the cost and time required for the identiﬁcation of clinically
useful personalized biomarkers.
4. Methods
4.1. Sample preparation and whole genome sequencing
Biopsies from six locally advanced rectal tumorswere obtained from
patients treated at the Instituto Angelita & Joaquim Gama/Hospital
Alemão Oswaldo Cruz (http://www.hospitalalemao.org.br). Tumor
samples were collected after informed consent and approval of the
institution's ethics committee. Blood samples from the same patients
were also collected and circulating leucocytes were used as a source of
normal matched germline DNA. Genomic DNA was extracted using a
Trizol based protocol for simultaneous DNA/RNA extraction [27].
Mate-pair libraries were generated for the SOLiD platform according
to the manufacturer's instructions. In brief, 5 ug of whole genome am-
pliﬁed (WGA) DNA samples were randomly sheared into 0.6–1.0 kb
fragments using the Covaris S2 System. Fragmented DNA was size se-
lected on 0.8% agarose gels and used as template in emulsion PCR.
DNA fragmentswere coupled to bead via an adapter sequence and clon-
ally ampliﬁed. Ampliﬁed DNA fragments were then covalently attached
to a glass slide. Sequencing primers hybridized to the adapter sequence
and ﬂuorescently labeled di-base probes were used in ligation-based
sequencing generating 50 nt mate-pair reads.
4.2. Read alignment and selection of discordant mate pairs
ICRmax starts from sequence alignment data against the human ref-
erence genome in .bam format allowing users to apply their algorithm
of choice for the alignment of mate-pair or pair-end reads. For the
rectal tumor samples, all color space reads were aligned using standard
BioScope mapreads (Applied Biosystems) algorithm against hg19/
GRCh37 reference sequence downloaded from UCSC Genome Browser
(http://genome.ucsc.edu/) [28]. Only sequences with unique mapping
and mapping quality greater than or equal to 20 (Q ≥20) are used in
subsequent steps. Once the reads are paired, their orientation andmap-
ping position are analyzed. Read pairs presenting an alignment against
the human reference genome in the expected orientation and within
expected distance (mean insert size+/− 2 s.d.) are discardedwhile ab-
errant pairs with readsmapping on different chromosomes are retained
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mate pairs with anomalous mapping patterns can be selected to search
for intrachromosomal rearrangements such as insertions, deletions and
inversions [29].
In order to minimize reference genome assembly errors and struc-
tural polymorphisms, selected read pairs are submitted through a sec-
ond mapping step using alternative human genome assemblies and
read pairs mapping on the same chromosome are excluded. Three
alternative genome assemblies were used as reference: HuRef (J. Craig
Venter Institute) [30], GRCh37_alt (partial reference genome with
alternative representations — Genome Reference Consortium) and
CRA (human chr7 complete sequence — The Center for Applied Geno-
mics) [31]. After mapping, all cases where both reads in a mate pair
map in the same chromosome were removed from further analysis.
All reads with identical mapping coordinates (identical start or end
positions) are removed from further analysis, since they likely result
from PCR duplicates generated during the library construction and
ampliﬁcation steps and can provide sequencing support to a false
positive candidate [32–34].
4.3. Rearrangement identiﬁcation
Sequences mapped inside centromeric (+1 Mb) and telomeric re-
gions (+1 Mb), downloaded from UCSC Genome Browser – http://
genome.ucsc.edu, are removed from the bed ﬁles with paired reads
using Bedtools [35] as detailed in the supplementary material. Read
pairs with sequences mapping to some of the regions deﬁned by
RepeatMasker [36] (LINEs, SINEs, low complexity regions, satellites
and rRNA genes), which may result in ambiguous mapping, are also re-
moved. Another ﬁltering step removes read pairs mapped in regions
corresponding to segmental duplications [37], in order to avoid false-
positive rearrangements caused by the misalignment of read pairs in
the parental and duplicated regions. Lastly we removed mate pairs
with reads mapping to the mitochondrial genome since we observed
that the presence of nuclear copies of mitochondrial DNA (numts) in
the nuclear genome [38] leads to misalignments and the identiﬁcation
of false-positives.
Finally, read pairs are grouped (clustered) based on their genomic
coordinates. Reads from different pairs mapped within a minimal dis-
tance corresponding to the average library insert size + 2 standard de-
viation (s.d.) on either side of the putative rearrangement are grouped.
For interchromosomal rearrangements, mate pairs with reads mapping
in the same two chromosomes are compared and reads from each pair
should map within a predetermined window to indicate the same
event (windows are calculated by adding 2 s.d. to mean insert size).
Once clusters are formed, the number of mate pairs supporting the
event is evaluated. Clusters composed of a minimum of three and a
maximum of 80 pairs are selected, reducing the impact of incorrect
mapping and other artifacts. The rational for setting the minimum and
maximumread support is related to the sequence coverage. Our sugges-
tion is to keep the “minimum” equal to or half of the sequence coverage
and the “maximum” (to avoid cluster with repetitive elements, which
are hard to validate) of ~20× the sequence coverage. Both the clustering
and this cutoff reduce substantially the number of reads indicating rear-
rangement events and simplify the last steps of the pipeline. For the
evaluation of the recurrent events, mate pair support was lowered to
two reads for the comparison between patients, keeping only events
in the ﬁnal set that could not be found in other patients even with the
lower support.
For SOLiD platform sequencing data, remaining reads are submitted
through a third and ﬁnal mapping step using BLAT [39] to remove fur-
ther unreliable read mapping that may result from the initial alignment
step for color space reads. Reads from a single mate pair showing other
mapping possibilities in the same chromosome and within expected
distance from their mate pairs are removed from the ﬁnal set. After re-
moving these mate pairs, the minimum read pair support should onceagain be evaluated and only clusters with at least two reads respecting
the same orientation pattern should bemaintained (see Supplementary
Fig. 1). BLAT parameters used were the same indicated for reproducing
the webtool results and can be found in Genome Browser [28,40].
4.4. 1000 Genomes data analysis
Whole genome sequencing data from 2362 individuals included in
the 1000 Genomes project were accessed through the Open Science
Data Cloud (www.opensciencedatacloud.org) and submitted through
our ICRmax pipeline. We increased the minimum mate-pair support
for an interchromosomal event to 5 and the average size of insert
between mate-pairs considered was 300 nt as described [25].
4.5. Simulated datasets
Based on the human genome sequence (hg19), three sets (RG1, RG2
and RG3) of ICR were randomly generated by using Perl scripts. Brieﬂy,
we ﬁrst randomly selected a chromosome and a genomic coordinate,
followed by a second selection of another breakpoint in a different chro-
mosome. The FASTA sequences of both chromosomes involved in the
rearrangements were joined, creating a new chromosome. This process
was repeated 20× for RG1, 30× for RG2 and 40× for RG3 (Table S3).
Chromosomes that were not involved in any simulated rearrangement
were also kept in the ﬁnal ﬁle. Finally, these genomes were then used
to simulate color space sequenced reads with 50 bp and 700 bp insert
size between mate pair reads. In order to simulate the real sequencing,
the generated reads contain 1% sequencing errors. The number of reads
generated was calculated based on the sequence and physical coverage
we wished to obtain for each simulation relative to the size of the
reference human genome (hg19).
The HYDRA-SV algorithm was downloaded from code.google.com/
p/hydra-sv/. Following the example workﬂow in the documentation,
the parameters calculated were – mno 1350 (10 × m.a.d. of the
DNA fragment libraries as suggested), – mld 1000 (the same overlap
distance used in ICRmax clustering) and – m 5 (at least ﬁve mate-
pairs supporting the breakpoint).
4.6. Analysis of FFPE breast cancer samples
Whole genome sequencing data was downloaded from SRA (acces-
sion: PRJNA193652). We used a subset of the available data, 5 ﬁles from
each sample (IDC and Lymph) for each of 4 patients. We excluded pa-
tient 2 from the analysis since the authors found mouse genome con-
tamination in three libraries. We did not use patient 3 data for a more
homogeneous dataset, since the normal tissue available for this patient
was not derived from lymph node like the other 4 used. Downloaded
ﬁles were converted to FASTq ﬁles using the SRA Toolkit and reads
were aligned to hg19 using Bowtie2 [41]with the very-sensitive param-
eter. Reads with mapping quality greater than or equal to 20 were
submitted through the ICRmax pipeline.
4.7. Orientation patterns and primer design
Read orientation is also consideredwhen deﬁning the candidates for
interchromosomal rearrangements. For the true positive candidates,
mate pairs spanning a single breakpointwill show equal patterns of ori-
entation. In case of SOLiD sequencing, mate pairs indicating the same
breakpoint can be classiﬁed into four different patterns detailed in
Figure S1. After dividing remainingmate pairs into different orientation
patterns clusters still containing two or more mate pairs are chosen for
validation. Clusters can end up divided into two sets of orientations,
which most likely represent two separate breakpoints for an insertion
or translocation. After observing read orientation, support for the
ﬁnal clusters is lowered to at least two mate pairs indicating the
rearrangement.
271E.R. Donnard et al. / Genomics 105 (2015) 265–2724.8. Breakpoint validation by PCR and sequencing
Primers were designed for a randomly chosen subset of the identi-
ﬁed rearrangements for each patient. Mate-pair sequences ﬂanking
predicted breakpoints were used as target sequences for primer design
using Primer3 when possible, with further manual evaluations neces-
sary to adjust the sequences to the target regions. Mate-pair sequence
order and orientation were used to guide primer design. When primers
could not be designed frommate-pair sequences, upstreamgenomic se-
quence up to 200 bpwas used for primer design. Primers were used for
PCR on tumor and matched normal samples to conﬁrm the somatic
origin and tumor-speciﬁcity of the rearranged fragments. Sanger
sequencing of PCR products was used to conﬁrm the speciﬁcity of the
PCR ampliﬁcation and to map breakpoint sequences.
5. Data access
The sequences used in this analysis will be submitted to The
European Nucleotide Archive (ENA; www.ebi.ac.uk/ena) under acces-
sion number PRJEB4781. Additional ﬁles can be obtained at http://
www.bioinfo.mochsl.org.br/icrmax.
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